p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells

Front Immunol. 2021 Aug 9:12:698565. doi: 10.3389/fimmu.2021.698565. eCollection 2021.

Abstract

T-cell dysfunction arising upon repeated antigen exposure prevents effective immunity and immunotherapy. Using various clinically and physiologically relevant systems, we show that a prominent feature of PD-1-expressing exhausted T cells is the development of cellular senescence features both in vivo and ex vivo. This is associated with p16INK4a expression and an impaired cell cycle G1 to S-phase transition in repeatedly stimulated T cells. We show that these T cells accumulate DNA damage and activate the p38MAPK signaling pathway, which preferentially leads to p16INK4a upregulation. However, in highly dysfunctional T cells, p38MAPK inhibition does not restore functionality despite attenuating senescence features. In contrast, p16INK4a targeting can improve T-cell functionality in exhausted CAR T cells. Collectively, this work provides insights into the development of T-cell dysfunction and identifies T-cell senescence as a potential target in immunotherapy.

Keywords: CAR T cells; T cells; adoptive immunotherapy; cellular senescence; exhaustion and activation markers; p16INK4a; p38MAPK.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • Cellular Senescence / immunology*
  • Cyclin-Dependent Kinase Inhibitor p16 / immunology*
  • Humans
  • Lymphocyte Activation / immunology*
  • Mice
  • Mice, Inbred C57BL
  • Programmed Cell Death 1 Receptor / immunology*

Substances

  • CDKN2A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor